Varied Outcomes Predicted On Icahn's Bid For Four Seats On Genzyme's Board
This article was originally published in The Pink Sheet Daily
Executive Summary
Activist investor Carl Icahn seeking the kind of gains similar to those he realized at Biogen Idec.